Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific

GenAI adoption in medical instruments is accelerating, with the AI-enabled medical devices market projected to grow at a 19.9% CAGR through 2026–2034; medical technology M&A totaled $36.5 billion in first-half 2026. The industry has gained 2.7% over the past year, lagging the healthcare sector’s 4.1% and the S&P 500’s 15.4%, while trading at 26.57x forward earnings versus 20.66x and 19.76x, respectively. The outlook highlights Globus Medical, Intuitive Surgical and Thermo Fisher Scientific, alongside risks from Middle East conflict and inflation projected at 4.7% in 2026.

Analysis

The investable distinction is not “AI exposure” but who can turn software into higher device utilization, recurring consumables, or defensible workflow lock-in. GenAI market-growth forecasts do not establish pricing power for device makers; near term, implementation, validation, privacy, and regulatory costs may accrue before customers pay for incremental functionality. Large installed-base platforms are better positioned to absorb those costs, while standalone features risk commoditization by general-purpose models.

ISRG has the clearest operating read-through in the material: procedure growth can support system utilization and recurring instrument demand without relying on GenAI monetization. Track procedure growth, placements, and recurring revenue at the next results; deceleration would undermine the thesis. GMED’s digital acquisition could reinforce its surgeon ecosystem, but value depends on adoption and cross-selling—not the acquisition announcement. TMO’s exposure is more indirect through research productivity and biopharma activity; do not treat it as a pure-play AI beneficiary.

At the industry level, a premium multiple alongside relative share-price underperformance leaves room for recovery, but also makes a broad rerating vulnerable if earnings estimates fail to convert. In the next 1–3 months, results and guidance matter more than market-size forecasts. Over 6–18 months, FDA and EU requirements could raise compliance costs and favor scaled incumbents, but could also slow product launches. M&A adds integration and regulatory risk; the article provides no deal-spread or financing data to support an event trade. Contrarian point: adoption statistics measure deployment, not paid usage or margin contribution.

Key Decisions for Investors

• Prefer a conditional, event-led long in ISRG over a broad MedTech/AI basket: consider entry on a post-results pullback only if procedure growth and recurring-use economics remain firm. Reassess if procedure growth materially decelerates or guidance is cut; confirm current valuation and positioning before sizing.
• Keep GMED on an execution watchlist rather than buying the AI narrative. Verify Higgs Boson Health customer adoption, cross-selling, and any disclosed revenue contribution; absent evidence of monetization, treat the acquisition as strategic optionality, not an earnings catalyst.
• Avoid treating TMO as a direct GenAI beneficiary. Monitor biopharma customer spending, instrument demand, and 2026 guidance revisions; weaker demand would outweigh speculative productivity benefits.
• Do not initiate a sector-wide AI trade from adoption or CAGR forecasts alone. Revisit if companies disclose paid AI usage, measurable procedure or workflow efficiency, and incremental margins; watch FDA rulemaking and EU compliance requirements for launch delays or cost increases.